BMS, AbbVie land Breakthrough label

Share this article:

Bristol-Myers Squibb and AbbVie pocketed a Breakthrough Therapy designation for the experimental multiple myeloma medication elotuzumab.

The companies announced the expedited FDA review classification of their monoclonal antibody Monday. The experimental drug is being investigated for use in tandem with lenalidomide and dexamethasone for patients who have already received at least one or two rounds of prior therapy.

The companies said the FDA handed over the label based on open-label Phase-II data.

BMS and AbbVie are co-developing the drug, and BMS is taking the lead on its commercialization.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.